title: Efficacy and pharmacokinetics of gallopamil in patients with coronary artery disease.
abstract: We prospectively studied 10 patients with stable exertional ischaemia, selected from a larger group of patients referred for suspected coronary artery disease or to detect residual ischaemia after myocardial infarction, to evaluate pharmacokinetic changes during chronic treatment with gallopamil and its correlation with clinical efficacy in patients with coronary artery disease. Our study consisted of a 1-week run-in single-blind placebo treatment and a 4-week single-blind gallopamil treatment. At the end of the run-in period patients underwent two different exercise tests, the first 2 hours and the second 7 hours after placebo administration. During active treatment all patients underwent two different exercise tests, the first 2 hours and the second 7 hours after gallopamil (50 mg) administration on the 1st and 28th days of gallopamil therapy. On the same days in eight of the patients we evaluated gallopamil pharmacokinetic changes. Our data revealed a rapid increase of unchanged gallopamil and its metabolite (norgallopamil) in the plasma, and a peak concentration of these substances about 2 hour after oral administration on both the 1st and 28th day of observation. Moreover, our results demonstrated an increase between the first and 28th day of treatment in peak concentration of unchanged gallopamil in the plasma, and of AUC 0-infinity and AUC o-c values during chronic treatment with gallopamil. Our clinical data showed an improvement in exercise results during gallopamil therapy related to increased concentration of the drug.
authors.affiliation: Division of Cardiology, Salvatore Maugeri Foundation, IRCCS, Rehabilitation Institute of Campoli Monte, Taburno (BN), Italy.
authors.forename: N
authors.initials: N
authors.lastname: Ferrara
authors.forename: G
authors.initials: G
authors.lastname: Longobardi
authors.forename: N
authors.initials: N
authors.lastname: Guerra
authors.forename: A
authors.initials: A
authors.lastname: Nicolino
authors.forename: D
authors.initials: D
authors.lastname: Acanfora
authors.forename: G
authors.initials: G
authors.lastname: Furgi
authors.forename: L
authors.initials: L
authors.lastname: Odierna
authors.forename: R
authors.initials: R
authors.lastname: Rosiello
authors.forename: F
authors.initials: F
authors.lastname: Rengo
mesh_terms: D000368:Aged; D002121:Calcium Channel Blockers / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D003327:Coronary Disease / Q000188:drug therapy* / Q000378:metabolism*; D004334:Drug Administration Schedule; D005080:Exercise Test / Q000187:drug effects; D005260:Female; D005711:Gallopamil / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010919:Placebos; D011446:Prospective Studies; D016037:Single-Blind Method
chemical_list: D002121:Calcium Channel Blockers; D010919:Placebos; D005711:Gallopamil